BD (Becton, Dickinson and Co.) gained U.S. FDA clearance for its BD Phoenix CPO detect test. It is used to identify infections caused by carbapenemase-producing organisms (CPOs). Typically, these are antimicrobial resistant infections that result in very high mortality rates. The test will be included on BD Phoenix gram-negative panels that offer antibiotic susceptibility testing to identify the best treatment for a specific infection. Read More
